AstraZeneca: shares up on new data for Farxiga and Brilinta
(CercleFinance.com) - AstraZeneca's Farxiga significantly reduced both the incidence of cardiovascular death and the worsening of heart failure in a phase III trial, new data showed on Monday.
The trial investigated the treatment of heart failure in patients with reduced ejection fraction (HFrEF), with and without type-2 diabetes.
Farxiga is currently approved to treat patients with type-2 diabetes.
AstraZeneca also presented positive results that showed that Brilinta reduced the risk of cardiovascular events in patients with coronary artery disease and type-2 diabetes.
The drugmaker said it plans to work with regulators to explore an update to the Brilinta label based on these results.
AstraZeneca shares were up 2.5% in London after these results.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The trial investigated the treatment of heart failure in patients with reduced ejection fraction (HFrEF), with and without type-2 diabetes.
Farxiga is currently approved to treat patients with type-2 diabetes.
AstraZeneca also presented positive results that showed that Brilinta reduced the risk of cardiovascular events in patients with coronary artery disease and type-2 diabetes.
The drugmaker said it plans to work with regulators to explore an update to the Brilinta label based on these results.
AstraZeneca shares were up 2.5% in London after these results.
Copyright (c) 2019 CercleFinance.com. All rights reserved.